News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Innova Biosciences And TGR Biosciences Announce Co-Marketing Agreement For Core Technologies

1/16/2014 9:12:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Cambridge, UK and Adelaide, Australia, 16 January 2014: TGR BioSciences Pty Ltd (TGR), a life sciences company focused on the development of rapid, high sensitivity ELISA systems using their CaptSure technology, and Innova Biosciences (Innova), a specialist provider of bioconjugation systems, announced that they have entered into an agreement to promote and co-market each other’s highly complementary technologies, providing customers with a major step forward in simplifying the ELISA development process, while improving sensitivity and reducing costs.

TGR has determined that combining Innova’s Lightning-Link conjugation kits for the horseradish peroxidase (HRP) labelling of antibodies with its CaptSure technology in the development of ELISA systems maximises assay sensitivity, whilst enabling the development of a wide range of ELISA assays rapidly and cost effectively. As part of the agreement Innova customers will be introduced to the CaptSure technology, with the assurance that it will work alongside the Lightning-Link reagents. Similarly, TGR customers will receive a recommendation for Lightning-Link, with the knowledge that it will be available for licensing to them, should they choose to use it alongside CaptSure products.

TGR’s CaptSure technology simplifies ELISA assays to one-step procedures, making them much faster and easier to carry out. Both assay antibodies are added to analyte at once, and after a single wash step the HRP substrate is added to develop the signal. Importantly, costs of manufacture are greatly reduced, since only a single assay plate is required (coated with CaptSure reagent) rather than a different plate for each target, and the system also requires much less assay antibodies.

Innova’s Lightning-Link conjugation system provides the ability to label antibodies with only 30 seconds hands-on time, whilst offering 100% yields and enhanced sensitivity over traditional labelling techniques and over other conjugation systems on the market.

Dr Michael Crouch, Director of Business Development at TGR, said: “We’ve been impressed with Innova’s products. Their HRP conjugation kit is simple to use and at the same time provides performance that exceeds that of a range of other systems that we have tested. We are very happy to recommend Lightning-Link to anyone who is developing assays with our CaptSure system.”

Dr Andy Lane, Executive Director at Innova Biosciences, said: "We are pleased to further develop our relationship with TGR. Their CaptSure technology provides advantages in ELISA assay development that are directly complementary to the ethos of our conjugation technology – simplicity, high speed and enhanced sensitivity.”

Media contacts

Lorna Cuddon, Zyme Communications


Phone: +44 (0)7811996942

At Innova Biosciences

Dr Andy Lane, Executive Director


Phone: +44 (0) 1223 496 170

At TGR BioSciences

Dr Michael Crouch, Director, Business Development


Phone: +61 (0)8 8354 6180

About TGR Biosciences

TGR BioSciences Pty Ltd (TGR) is an innovative private biotechnology company based in Adelaide, South Australia, specializing in the development of immunoassay technologies and products to serve the global research and discovery markets. TGR has on market a broad portfolio of state-of-the-art assays for cell based analysis of GPCRs, kinases and cell signalling pathways, supplying major pharmaceutical and biotechnology companies, and academic laboratories worldwide. TGR is actively developing further novel protein analysis technologies to advance research in other key therapeutic areas.

For more information, please visit

About Innova Biosciences Limited

Innova Biosciences is a growing, dynamic, ISO 9001:2008 business based in Cambridge, UK. At the core of Innova's business are the Lightning-Link®, InnovaCoat® and Thunder-Link® technologies, which simplify the production of antibody-based reagents. The expanding portfolio is sold to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide.

For more information, please see

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus